このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

The Effect of Smoking on Salivary and Serum Lipidomic Profiles in Patients With Periodontitis

2026年11月11日 更新者:Nihan AKDOĞAN、Ankara University

This observational study aims to investigate how smoking and periodontal health affect lipid profiles in saliva and blood serum. Periodontitis is a chronic inflammatory disease that affects the tissues supporting the teeth, while smoking is an important risk factor for periodontal disease.

The study will include 56 adults divided into four groups according to their periodontal health and smoking status: non-smokers with periodontitis, smokers with periodontitis, periodontally healthy non-smokers, and periodontally healthy smokers.

Saliva and blood samples will be collected from each participant. Lipid profiles will be analyzed using liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (LC-qTOF-MS). The study will examine the individual and combined associations of periodontitis and smoking with lipid profiles and explore the relationship between lipid patterns in saliva and serum.

The findings may help identify lipid-related changes associated with periodontal disease and smoking and improve our understanding of their effects on oral and systemic health.

調査の概要

詳細な説明

Periodontitis is a chronic inflammatory disease characterized by the destruction of tooth-supporting tissues. Smoking is a major modifiable risk factor that influences periodontal inflammation, host immune responses, and disease progression. Both periodontitis and smoking may alter lipid metabolism and contribute to oxidative stress and inflammatory processes.

Lipidomics provides a comprehensive approach to investigating lipid species and metabolic alterations associated with disease. Saliva is a non-invasive biological fluid that may reflect both local oral conditions and systemic biological processes. Comparing salivary and serum lipidomic profiles may provide further insight into the metabolic changes associated with periodontal disease and smoking.

This observational, cross-sectional study will enroll 56 adults aged 18-65 years. Participants will be categorized into four groups based on periodontal status and smoking habits: periodontitis with smoking, periodontitis without smoking, periodontal health with smoking, and periodontal health without smoking.

Periodontal status will be determined through clinical periodontal examination. Saliva and blood samples will be obtained from the same participants, and untargeted lipidomic profiling will be performed using liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (LC-qTOF-MS).

The study will assess the associations of periodontal status and smoking with salivary and serum lipidomic profiles, including their potential interaction. Relationships between lipidomic patterns in the two biological fluids will also be investigated.

This study is expected to contribute to a better understanding of lipid-related biological alterations associated with periodontitis and smoking and may support future research into potential biomarkers of periodontal disease.

研究の種類

観察的

入学 (推定)

56

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~65年 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

The study population will consist of 56 adults aged 18-65 years, categorized into four groups according to periodontal status and cigarette smoking: (1) patients with periodontitis who smoke, (2) patients with periodontitis who do not smoke, (3) periodontally healthy individuals who smoke, and (4) periodontally healthy individuals who do not smoke. Participants will be evaluated through clinical periodontal examinations, and saliva and serum samples will be collected for lipidomic profiling. All participants must meet the predefined eligibility criteria.

説明

Inclusion Criteria:

Individuals aged 18 years or older. Individuals who do not use orthodontic appliances Women who are not pregnant or breastfeeding. Individuals without systemic diseases that may affect periodontal health. Individuals who have not used anti-inflammatory and/or antimicrobial medications within the past 6 months.

Individuals who have not received periodontal treatment within the past year.

Exclusion Criteria:

Individuals younger than 18 years. Individuals older than 65 years. Pregnant or breastfeeding women. Individuals who have used anti-inflammatory and/or antimicrobial medications within the past 6 months.

Individuals who have received periodontal treatment within the past year. Individuals with psychiatric disorders. Individuals with any oral infection. Individuals with alcohol dependence. Individuals with active infectious diseases (acute hepatitis, AIDS, or tuberculosis), cancer, or any systemic disease that may affect periodontal tissues.

Individuals receiving medications known to affect periodontal tissues, including phenytoin, cyclosporine A, or calcium channel blockers.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:CROSS_SECTIONAL

コホートと介入

グループ/コホート
介入・治療
Periodontitis Smokers

Adult participants diagnosed with periodontitis who are current cigarette smokers. Saliva and serum samples will be collected for lipidomic profiling.

Saliva samples will be collected from all participants and analyzed using mass spectrometry-based lipidomic techniques to characterize salivary lipid profiles and investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered.

Blood samples will be collected from all participants, and serum will be separated for lipidomic analysis using mass spectrometry-based techniques. Serum lipid profiles will be evaluated to investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered.

Probing pocket depth (PPD) will be measured in millimeters using a periodontal probe at six sites per tooth. Measurements will be recorded to assess periodontal pocket depth and periodontal disease severity.

Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Measurements will be recorded to assess the extent of periodontal attachment loss and periodontal disease severity.

Bleeding on probing (BOP) will be assessed at six sites per tooth during periodontal probing. The percentage of sites exhibiting bleeding will be calculated to evaluate gingival inflammation.

Plaque index (PI) will be assessed during the clinical periodontal examination to evaluate dental plaque accumulation. Plaque scores will be recorded according to the study protocol.

Periodontitis Non-Smokers

Adult participants diagnosed with periodontitis who are non-smokers. Saliva and serum samples will be collected for lipidomic profiling.

Saliva samples will be collected from all participants and analyzed using mass spectrometry-based lipidomic techniques to characterize salivary lipid profiles and investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered.

Blood samples will be collected from all participants, and serum will be separated for lipidomic analysis using mass spectrometry-based techniques. Serum lipid profiles will be evaluated to investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered.

Probing pocket depth (PPD) will be measured in millimeters using a periodontal probe at six sites per tooth. Measurements will be recorded to assess periodontal pocket depth and periodontal disease severity.

Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Measurements will be recorded to assess the extent of periodontal attachment loss and periodontal disease severity.

Bleeding on probing (BOP) will be assessed at six sites per tooth during periodontal probing. The percentage of sites exhibiting bleeding will be calculated to evaluate gingival inflammation.

Plaque index (PI) will be assessed during the clinical periodontal examination to evaluate dental plaque accumulation. Plaque scores will be recorded according to the study protocol.

Periodontally Healthy Smokers

Adult participants with clinically healthy periodontal tissues who are current cigarette smokers. Saliva and serum samples will be collected for lipidomic profiling.

Saliva samples will be collected from all participants and analyzed using mass spectrometry-based lipidomic techniques to characterize salivary lipid profiles and investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered.

Blood samples will be collected from all participants, and serum will be separated for lipidomic analysis using mass spectrometry-based techniques. Serum lipid profiles will be evaluated to investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered.

Probing pocket depth (PPD) will be measured in millimeters using a periodontal probe at six sites per tooth. Measurements will be recorded to assess periodontal pocket depth and periodontal disease severity.

Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Measurements will be recorded to assess the extent of periodontal attachment loss and periodontal disease severity.

Bleeding on probing (BOP) will be assessed at six sites per tooth during periodontal probing. The percentage of sites exhibiting bleeding will be calculated to evaluate gingival inflammation.

Plaque index (PI) will be assessed during the clinical periodontal examination to evaluate dental plaque accumulation. Plaque scores will be recorded according to the study protocol.

Periodontally Healthy Non-Smokers

Adult participants with clinically healthy periodontal tissues who are non-smokers. Saliva and serum samples will be collected for lipidomic profiling.

Saliva samples will be collected from all participants and analyzed using mass spectrometry-based lipidomic techniques to characterize salivary lipid profiles and investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered.

Blood samples will be collected from all participants, and serum will be separated for lipidomic analysis using mass spectrometry-based techniques. Serum lipid profiles will be evaluated to investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered.

Probing pocket depth (PPD) will be measured in millimeters using a periodontal probe at six sites per tooth. Measurements will be recorded to assess periodontal pocket depth and periodontal disease severity.

Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Measurements will be recorded to assess the extent of periodontal attachment loss and periodontal disease severity.

Bleeding on probing (BOP) will be assessed at six sites per tooth during periodontal probing. The percentage of sites exhibiting bleeding will be calculated to evaluate gingival inflammation.

Plaque index (PI) will be assessed during the clinical periodontal examination to evaluate dental plaque accumulation. Plaque scores will be recorded according to the study protocol.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Salivary Lipidomic Profile
時間枠:At baseline (single sample collection)

Salivary lipid species and their relative abundances will be measured using mass spectrometry-based lipidomic analysis. Lipidomic profiles will be compared across four groups according to periodontal status and cigarette smoking status.

At baseline (single sample collection)
Serum Lipidomic Profile
時間枠:At baseline (single sample collection)

Serum lipid species and their relative abundances will be measured using mass spectrometry-based lipidomic analysis. Lipidomic profiles will be compared across four groups according to periodontal status and cigarette smoking status.

At baseline (single sample collection)

二次結果の測定

結果測定
メジャーの説明
時間枠
Probing Pocket Depth (PPD)
時間枠:At baseline (single clinical examination)

Probing pocket depth (PPD) will be measured in millimeters at six sites per tooth using a periodontal probe. Mean PPD values will be calculated to characterize periodontal status, evaluate differences between study groups, and investigate correlations with salivary and serum lipidomic profiles.

At baseline (single clinical examination)
Attachment Loss (AL)
時間枠:At baseline (single clinical examination)

Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Mean AL values will be calculated to characterize periodontal tissue destruction, evaluate differences between study groups, and investigate correlations with salivary and serum lipidomic profiles.

At baseline (single clinical examination)
Bleeding on Probing (BOP)
時間枠:At baseline (single clinical examination)

Bleeding on probing (BOP) will be assessed at six sites per tooth. The percentage of sites exhibiting bleeding will be calculated to characterize gingival inflammation, evaluate differences between study groups, and investigate correlations with salivary and serum lipidomic profiles.

At baseline (single clinical examination)
Plaque Index (PI)
時間枠:At baseline (single clinical examination)

Plaque index (PI) will be assessed to quantify dental plaque accumulation. Individual plaque index scores will be calculated according to the study protocol to characterize oral hygiene status, evaluate differences between study groups, and investigate correlations with salivary and serum lipidomic profiles.

At baseline (single clinical examination)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年11月11日

一次修了 (推定)

2026年12月31日

研究の完了 (推定)

2026年12月31日

試験登録日

最初に提出

2026年11月11日

QC基準を満たした最初の提出物

2026年11月11日

最初の投稿 (実際)

2026年11月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data (IPD) will not be shared with other researchers to protect participant confidentiality and privacy. Study findings will be reported in aggregate form through scientific publications without disclosing identifiable participant information.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する